Atsena Therapeutics
Dr. Mike Dial has extensive experience working with early-stage life science and healthcare companies. Dr. Dial joined Hatteras in 2009 from Silicon Valley Bank (SVB), where he was a Vice President in the Corporate Finance Group focused on emerging tech and life science companies and venture capital funds. Prior to SVB, he held research scientist positions in the Department of Biochemistry at the University of North Carolina (UNC) at Chapel Hill, the Genome Integrity and Structural Biology Laboratory at the National Institute of Environmental Health Sciences and the UNC Michael Hooker Proteomics Center. He has performed research in the fields of cell cycle regulation, proteomics and cancer therapy.
Dr. Dial is a Professor of the Practice at the Kenan-Flagler Business School at UNC-Chapel Hill and is the Manager for the Carolina Research Venture Fund. He holds a PhD in Biochemistry and Biophysics from UNC-Chapel Hill.
This person is not in the org chart
This person is not in any offices
Atsena Therapeutics
Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. They have an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Their additional pipeline of leading preclinical assets is powered by an adeno-associated virus (AAV) technology platform tailored to overcome significant hurdles presented by inherited retinal disease.